Vaxart, Inc. Files 8-K on Financials
Ticker: VXRT · Form: 8-K · Filed: Mar 14, 2024 · CIK: 72444
| Field | Detail |
|---|---|
| Company | Vaxart, Inc. (VXRT) |
| Form Type | 8-K |
| Filed Date | Mar 14, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k, disclosure
Related Tickers: VXRT
TL;DR
Vaxart dropped its 8-K, check the financials.
AI Summary
Vaxart, Inc. filed an 8-K on March 14, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, providing an update on the company's financial status. No specific dollar amounts or new operational details were immediately apparent in the provided text, but the filing serves as a standard disclosure for public companies.
Why It Matters
This filing provides investors with an update on Vaxart's financial health and operational status, which is crucial for understanding the company's current performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for financial reporting and does not appear to contain any new material adverse information.
Key Players & Entities
- Vaxart, Inc. (company) — Registrant
- March 14, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 001-35285 (identifier) — SEC File Number
- 59-1212264 (identifier) — IRS Employer Identification No.
- Aviragen Therapeutics, Inc. (company) — Former Company Name
- Biota Pharmaceuticals, Inc. (company) — Former Company Name
- NABI BIOPHARMACEUTICALS (company) — Former Company Name
FAQ
What specific financial information is being disclosed in this 8-K filing?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits', but the specific details are not provided in the header.
When was this 8-K report filed?
The report was filed on March 14, 2024.
What is Vaxart, Inc.'s SEC file number?
Vaxart, Inc.'s SEC file number is 001-35285.
In which state was Vaxart, Inc. incorporated?
Vaxart, Inc. was incorporated in Delaware.
What were Vaxart's previous company names?
Vaxart, Inc. was formerly known as Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., and NABI BIOPHARMACEUTICALS.
Filing Stats: 554 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2024-03-14 16:05:05
Key Financial Figures
- $0.0001 — nge on which registered Common Stock , $0.0001 par value VXRT The Nasdaq Capital M
Filing Documents
- vxrt20240312_8k.htm (8-K) — 32KB
- ex_638221.htm (EX-99.1) — 95KB
- 0001437749-24-007847.txt ( ) — 267KB
- vxrt-20240314.xsd (EX-101.SCH) — 3KB
- vxrt-20240314_def.xml (EX-101.DEF) — 11KB
- vxrt-20240314_lab.xml (EX-101.LAB) — 15KB
- vxrt-20240314_pre.xml (EX-101.PRE) — 11KB
- vxrt20240312_8k_htm.xml (XML) — 3KB
02
Item 2.02 Results of Operations and Financial Condition. On March 14, 2024, Vaxart, Inc. issued a press release announcing its financial results for the year ended December 31, 2023. A copy of this press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information in this report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying Exhibit 99.1 shall not be deemed incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Vaxart, Inc., whether made before or after the date hereof regardless of any general incorporation language in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Description 99.1 Press release, dated March 14, 2024, titled "Vaxart Provides Business Update and Reports Full Year 2023 Financial Results". 104 Cover Page Interactive Data File (embedded within Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Vaxart, Inc. Dated: March 14, 2024 By: /s/ MICHAEL J. FINNEY Michael J. Finney, Ph.D. Interim Chief Executive Officer and Chair of the Board of Directors